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Novel	  gene	  therapy	  approach	  combined	  with	  
an5-­‐TLR4	  monoclonal	  an5bodies	  in	  MPS	  VII.	  
The	   mucopolysaccharidosis	   (MPS)	   are	   a	   subset	   of	   lysosomal	   storage	   disorders	   characterized	   by	   deﬁciencies	   in	   enzymes	   that	   contribute	   to	  
degrada=on	  of	  glycosaminoglycans	  (GAGs).	  GAGs	  accumulate	   in	  the	   lysosome,	   leading	  to	  dysfunc=on	  in	  a	  variety	  of	  cell	   types	  and	  organs	  through	  
mechanisms	  that	  generally	  remain	  unclear.	  MPS	  are	  considered	  rare	  diseases	  due	  to	  its	  low	  incidence,	  which	  is	  es=mated	  in	  1	  of	  25.000	  live	  births.	  
Concretely,	  mucopolysaccharidosis	  type	  VII	  (MPS	  VII)	  is	  an	  autosomal	  recessive	  disorder	  caused	  by	  a	  severe	  deﬁciency	  in	  the	  ac=vity	  of	  the	  lysosomal	  
enzyme	  β-­‐glucuronidase,	  an	  enzyme	  involved	  in	  the	  stepwise	  degrada=on	  of	  GAGs.	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MPS	   pa=ents	   exhibit	   mul=-­‐systemic	   disease	   symptoms	   like	  
hepatosplenomegaly,	   corneal	   clouding,	   growth	   and	   mental	  
retarda=on,	   cardiac	   defects,	   and	   bone	   malforma=ons	   collec=vely	  
known	  as	  dysostosis	  mul=plex.	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Skeletal	  pathology	  becomes	  progressively	  worse	  with	  age,	  bones	  
develop	   poorly,	   are	   thick,	   short	   and	   angulated,	   leading	   to	  
dispropor=onal	  short	  stature.	  
The	  main	  objec=ve	   is	   to	  propose	  a	  PhD	   thesis	   that	  consists	   in	  a	  gene	  
therapy	  approach,	  which	  tries	  to	  revert	  mucopolysaccharidosis	  type	  VII	  
clinical	  features,	  concretely	  bone	  and	  joint	  complica=ons.	  
Ø  Preliminary	   informa=on	   of	   MPS	   VII	   pathogenesis	   and	  
complica=ons	  was	  collected	  from	  ar=cles	  and	  web	  sites	  (including	  
MPS	  Spain	  Associa=on).	  
	  
Ø  In	  order	  to	  not	  overlap	  previous	  knowledge	  and	  trying	  to	  propose	  
a	   novel	   approach,	   diﬀerent	   projects	   were	   consulted.	   Besides,	   a	  
virtual	   interview	  with	   the	  neuropediatrician	  Dr.	  Mercedes	  Pineda	  
Marfa	  from	  Sant	  Joan	  de	  Déu	  Hospital	  (Barcelona)	  was	  done.	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
The	  main	  problem	  is	  the	  delivery	  of	  the	  vector	  into	  bone	  and	  joints	  due	  to	  they	  
are	   compact	   and	   poorly	   irrigated	   =ssues.	   Besides,	   it	   is	   supposed	   to	   be	   an	  
ac=vity	   increment	   in	   the	   TLR4	   pathway	   of	   MPS	   VII	   pa=ents	   that	   causes	   an	  
enhanced	  expression	  of	  NF-­‐kB	  and	  a	   set	  of	  pro-­‐inﬂammatory	   cytokines.	   This	  
local	   increment	  of	  pro-­‐inﬂammatory	   implies	  a	  greater	  presence	  of	  an=bodies	  
and	   blocking	   agents	   that	   avoid,	   even	   more,	   the	   vector	   arrival	   to	   these	   cell	  
types	   and	   also	   induces	   apoptosis	   to	   chondrocytes	   of	   the	   growth	   plate.	  
Therefore,	  my	  proposal	  is	  a	  gene	  therapy	  approach	  in	  which,	  a	  len5viral	  virus	  
that	   carries	   a	   ubiquous	   and	   strong	   promoter	   (EF1α)	   upstream	   of	   cDNA	   of	  
GUSB	   combined	   with	   the	   injec5on	   of	   an5-­‐TLR4	   monoclonal	   an5bodies	   in	  
order	   to	   facilitate	   vector	   infec5on	   in	   bone	   and	   joints.	   In	   this	   PhD	   research	  
proposal	  I	  propose	  two	  main	  trials:	  	  
	  
1)  A	   gene	   therapy	   approach	   consis=ng	   of	   a	   single	   intravenous	   systemic	  
injec=on	   of	   len=viral-­‐vector	   in	   MPS	   VII	   dogs	   at	   birth,	   combined	   with	  
intravenous	  injec=on*	  of	  an=-­‐TLR4	  monoclonal	  an=bodies.	  
	  
2)  A	   gene	   therapy	   approach	   consis=ng	   of	   single	   intravenous	   injec=on	   of	  
len=viral-­‐vector	  in	  MPS	  VII	  3-­‐weeks-­‐old	  dogs	  aber	  several	  and	  con=nuous	  
join-­‐injec=ons*	  in	  synovial	  ﬂuid	  of	  an=-­‐TLR4	  monoclonal	  an=bodies	  during	  
development	  and	  mature	  adults	  dogs.	  
of inﬂammatory cytokines, proteases, and growth factors at the
sites of pathology (e.g., bone and cartilage) and into the circu-
lation. To investigate activation of the “GAG-speciﬁc” pathway,
we determined the levels of CD44 in MPS VI rat ﬁbroblast-like
synoviocytes (FLSs) and articular chondrocytes and found that the
expression of CD44 also was substantially elevated in MPS cells
(Fig. 1B). Thus, inMPS connective tissue, TLR4 activation occurs
via both the LPS- and GAG-speciﬁc pathways.
To examine TLR4 expression in MPS connective tissue cells
further, immunolocalization studies were carried out using MPS
VI rat FLSs (Fig. 2A). Consistent with our prior data (5), these
results revealed a high level of TLR4 colocalization in MPS lyso-
somes, likely attributable to accumulation within these dysfunc-
tional organelles.
Abnormal lysosomal and/or endosomal trafﬁcking occurs in
many lysosomal storage disorders, leading to enhanced apoptosis
and/or altered autophagy (16, 17). Autophagy is an important
normal function of the lysosomal/endosomal system and has
been shown to protect cells from inﬂammation caused by oxi-
dative stress (18). Because growth plate and articular chon-
drocytes are embedded in an avascular environment with a
limited oxygen upply, they particularly rely on autophagy to
sustain cell survival (19).
To examine autophagy in MPS, the levels of microtubule-
associated protein 1 light chain 3 (LC3-I) and its phosphatidy-
lethanolamine-conjugated form (LC3-II) were determined.
Conversion of LC3-I to LC3-II is a marker of autophagosome
formation (20). As shown in Fig. 2B, MPS VI rat FLSs accu-
mulate LC3-I predominantly, indicating little autophagosome
formation. In contrast, in MPS VI articular chondrocytes, LC3-I
was completely converted to LC3-II, suggesting an increased
number of autophagosomes. These data are consistent with
previous ﬁndings indicating that these two different MPS con-
nective tissue cell types have distinct pathological changes. Tes-
sitore et al. (8) also have shown that human MPS VI skin
ﬁbroblasts accumulate LC3-II.
To examine the physiological signiﬁca ce of TLR4 activation
in the MPS disorders gen tically, TLR4(lps−/−) mice were bred to
MPS VII mice to generative double-KO (DKO) mice. As shown
in Fig. 3A and Fig. S1A, inactivation of TLR4 in MPS VII mice
had a signiﬁcant positive effect on their growth. Quantitative
analysis similarly revealed longer and thinner faces in the DKO
mice when compared with MPS VII mice (Fig. 3B).
We also assessed the effects of TLR4 KO on the bones of MPS
VII mice by micro-computed tomography (CT) imaging and
histological analysis of their growth plates. Micro-CT revealed
longer femora in the DKO mice compared with age- and gender-
matched MPS VII mice (Fig. 3C), despite the fact that an os-
teopetrotic phenotype was still observed and bone density was
unchanged in the DKO mice. Fig. S1A graphically depicts the
femur and tibia lengths for all the MPS VII and DKO mice
analyzed. Both the femora and tibias of TLR4(lps−/−) control
mice were equivalent to those of age- and gender-matched
WT mice.
We also found that the growth plates of MPS VII mice were
thicker and more disorganized when compared with those of
TLR4(lps−/−) mice and were improved in the DKO mice (Fig. 3D
and Fig. S1B). However, despite these improvements, the en-
larged cells in the MPS VII growth plates remained in the DKO
mice. This may be expected, because the increased cell size in
MPS is likely attributable to GAG storage, which would not be
affected by TLR4 KO.
We also observed no differences in total cell numbers in the
MPS VII vs. control growth plates (Fig. S1C). This contrasts with
recent ﬁndings by Metcalf et al. (7), who showed reduced cell
numbers in the proliferative zone of MPS VII mice. This dif-
ference may be attributable to the fact that the mice in that study
CD44
PKCα
B Fibroblast-LikeSynoviocytes
Normal    MPS VI
Chondrocytes
Normal     MPS VI
TNF-
IL-1
GAG Fragments
CD44, MyD88
NF- B
T
L
R
-4
MMP-13
TGF-
A LPS
LBP, CD14, MyD88
Fig. 1. (A) TLR4 signaling pathway can be activated via GAG fragments
requiring CD44 and MyD88 or through LPS, which requires MyD88, LBP, and
CD14. (B) CD44 adhesion receptor (55 kDa) is a hyaluronan-binding cell
surface glycoprotein involved in the initiation of GAG-induced inﬂammation
via TLR4. Elevated CD44 expression was detected in 6-month-old MPS VI rat
FLSs and articular chondrocytes, conﬁrming the activation of TLR4 via the
GAG pathway in MPS. Protein kinase C-α (PKC-α; 82 kDa) was used as a
loading control.
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Fig. 2. Localization of TLR4 in MPS VI lysosomes. (A) Rat FLSs were in-
cubated with TLR4 primary polyclonal anti-rat antibody and LysoTracker
Green to visualize lysosomes. Visualization of TLR4 was accomplished using a
ﬂuorescent secondary antibody, Cy-3, and nuclei were stained with a bis-
benzamide Hoechst dye. Note the elevated levels of TLR4 in MPS VI cells and
colocalization with the LysoTracker Green dye. (B) Anti-LC3-I (14 kDa) and
LC3-II (16 kDa) Western blots of FLSs and articular chondrocytes from 6-
m nth-old normal and MPS VI rats showing the lack of conversion of the
LC3-I isoform to LC3-II in the FLSs. In contrast, in MPS VI articular chon-
drocytes, LC3-I was completely converted to LC3-II. Protein kinase C-α (Pkc-α)
was used as a loading control.
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Up	   regula=on	   of	   destruc=ve	   enzymes	   in	   MPS	   could	   induce	   inﬂammatory	  
pathways	   and	   altered	   growth	   of	   connec=ve	   =ssue	   and	   other	   cells	   through	  
ac=va=on	  of	  the	  Toll-­‐like	  receptor	  4	  (TLR4)	  signalling	  pathway.	  Liposaccharide	  
(LPS)	  is	  the	  classical	  ligand	  of	  TLR4	  but	  heparan	  sulfate,	  one	  of	  the	  GAGs	  that	  
accumulates	   in	  MPS	  VII,	  acts	  as	  an	  endogenous	   ligand	  of	  TLR4	  and	  ac=vates	  
an	  inﬂammatory	  response	  via	  the	  NFκB	  signalling	  pathway.	  
	  
Simonaro	  et	  al.,	  with	  the	  aim	  to	  examine	  the	  pathophysiological	  signiﬁcance	  
of	  TLR4	  ac=va=on	  in	  the	  MPS	  disorders,	  generated	  double-­‐KO	  (DKO)	  mice	  as	  
a	  result	  of	  crossing	  TLR4	  (LPS−/−)	  mice	  with	  MPS	  VII	  mice.	  
were 3 weeks of age, whereas they were 6 weeks of age in this
study. This difference in age can have a major impact on growth
plate development. For example, Ahmed et al. (21) have shown
that a secondary proliferative cluster of cells appears at 4 weeks
in the growth plates of “Tich” mice, leading to increased thick-
ness. In this model, as in MPS, these cells are dysfunctional and
do not result in calciﬁcation or bone growth. Given that cell size
and number were unchanged in the DKO animals, we hy-
pothesize that the improved bone length and size of the DKO vs.
MPS VII mice may be the result of increased endochondral
ossiﬁcation attributable to improved chondrocyte alignment
within the growth plate columns, contributing to a reduction in
growth plate width.
We next assessed the levels of phosphorylated STAT1 and
STAT3 in normal, TLR4(lps−/−), MPS VII, and DKO articular
chondrocytes by Western blot analysis (Fig. 3E). As reported by
others (7), MPS VII mice had elevated levels of p-STAT1-
Ser727 and repressed levels of p-STAT3-Tyr705, consistent with
activation of TLR4. The levels of p-STAT1-Ser727 and 3-Tyr705
in the DKO mice were normal, indicating that inactivation of the
TLR4 pathway in MPS VII mice corrected the abnormal
pSTAT1 and pSTAT3 expression.
Similar alterations in STAT1 and STAT3 have been observed
in rheumatoid arthritis (RA) and have been attributed to acti-
vation of TNF-α (22–24). We therefore assessed the serum levels
of TNF-α. The elevated levels seen in MPS VII mice were nor-
malized in DKO mice (Fig. 3F). TNF-α is an important down-
stream mediator of TLR4, and several investigators have
recently shown that TLR4 activation and/or TNF-α has im-
portant pathogenic effects in the brains of MPS mouse models
(6, 25). We therefore examined the locomotor behavior of the
DKO mice using an accelerating rotarod (Fig. 3G). At 5 months
of age, the performance of the DKO mice on the rotarod was
equivalent to that of control TLR4(lps−/−) mice, in contrast to
MPS VII mice, which were markedly defective. Although these
results are consistent with improved cerebellar function in the
DKO mice, rotarod locomotion is a complex task and the results
could also relate partially or wholly to improvements in the bones
and joints.
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Fig. 3. (A) MPS VII and TLR4(lps−/−) mice were crossed to produce a double-mutant (DKO) strain (MPS VII/TLR4(lps−/−)). Note the dramatic size difference between
MPS VII and DKO mice. Shown are representative 5-month-old TLR4(lps−/−), DKO, and MPS VII male mice. (B) Skull measurements, including width (A), length
(B), inner canthal distance (C), and nose widths (D), were taken of age- and gender-matched TLR4(lps−/−), DKO, and MPS VII male mice (n = 6). TLR4(lps−/−) mice
had skull measurements that were equivalent to normal. A signiﬁcant increase in skull length and reduction in width were observed in the DKO mice compared
with the MPS VII mice. *P < 0.001. (C) Micro-CT analysis was performed on femora from TLR4(lps−/−), DKO, and MPS VII male mice (n = 6). A representative image
is shown, revealing that the bones were signiﬁcantly longer in DKO vs. MPS VII mice. (D) Representative images of the growth plates from TLR4(lps−/−), MPS
VII, and DKO mice. Note that the growth plates were thinner in DKO vs. MPS VII mice and that the columns were more organized. (Scale bar: 15 μm.) (E) Levels
of p-STAT1-Ser727 (90 kDa) and p-STAT3-Tyr705 (90 kDa) were analyzed by Western blotting in normal, MPS VII, TLR4(lps−/−), and DKO mice. β-Actin was used as
a loading control (46 kDa). MPS VII mice had elevated p-STAT1-Ser727 and reduced p-STAT3-Tyr705; these were corrected in the DKO mice. (F) TNF-α serum
levels were analyzed by ELISA in 5-month-old TLR4(lps−/−) (gray bar), MPS VII (white bar), and DKO (black bar) mice (n = 6). Signiﬁcantly elevated TNF-α levels
were evident in the MPS VII mice, which were normalized in the DKOmice. (G) Male 5-month-old TLR4(lps−/−) (gray bar), MPS VII (white bar), and DKO (black bar)
mice were placed on an accelerating rotarod to assess coordination and mobility (n = 6). The MPS VII mice could not complete the task and fell off between
54 (0.38 m) and 75 (0.70 m) sec after initiating the run. In contrast, the DKO mice completed the 120-sec (1.4 m) task, equivalent to the control TLR4(lps−/−) mice.
*P < 0.001.
224 | www.pnas.org/cgi/doi/10.1073/pnas.0912937107 Simonaro et al.
were 3 weeks of age, whereas they were 6 weeks of age in this
study. This difference in age can hav a major impact on growth
plat development. For example, Ahmed et al. (21) have shown
that a secondary proliferative cluster of cells appears at 4 w eks
in the growth plates of “Tich” mice, leading to increased thick-
ness. In this model, as in MPS, these cells are dysfunctional and
do n t esult in calciﬁcation or bone growth. Given t at cell size
and nu ber were unchanged in the DKO animals, we hy-
pothesize that the improved bone length and size of the DKO vs.
MPS VII mice may be the result of increased endochondral
ossiﬁcation attributable to improved chondrocyte alignment
within the growth plate columns, contributing to a reduction in
growth plate width.
We ext assessed the levels of phosphorylated STAT1 and
STAT3 in normal, TLR4(lps−/−), MPS VII, and DKO articular
chondrocytes by Western blot analysis (Fig. 3E). As reported by
others (7), MPS VII mice had elevated levels of p-STAT1-
Ser727 and repressed levels of p-STAT3-Tyr705, consistent with
activation of TLR4. The levels of p-STAT1-Ser727 and 3-Tyr705
in the DKO mice were normal, indicating that inactivation of the
TLR4 pathway in MPS VII mice correct d the abnor al
pSTAT1 and pSTAT3 expression.
Similar alterations in STAT1 and STAT3 have b en observed
in rheu atoid arthritis (RA) and have been attributed to acti-
vation of TNF-α (22–24). We th refore assessed the serum levels
of TNF-α. The elevated levels seen in MPS VII mice were nor-
malized in DKO mice (Fig. 3F). TNF-α is an important down-
stream mediator of TLR4, and several investigato s have
recently shown that TLR4 activation and/or TNF-α has im-
portant pathogenic effects in the brains of MPS mouse models
(6, 25). We therefore examined the locomotor behavior of the
DKO mice using n accelerating rotarod (Fig. 3G). At 5 onths
of age, the performance of the DKO mice on the rotarod was
equivalent to that of control TLR4(lps−/−) mice, in contrast to
MPS VII mice, which were markedly defective. Although these
results are consistent with improved cerebellar function in the
DKO mice, rotarod locomotion is a complex task and the results
could also relate partially or wholly to improvements in the bones
and joints.
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Fig. 3. (A) MPS VII and TLR4(lps−/−) mice were crossed to produce a double-mutant (DKO) strain (MPS VII/TLR4(lps−/−)). Note the dramatic size difference between
MPS VII and DKO mice. Shown are representative 5-month-old TLR4(lps−/−), DKO, and MPS VII al mice. (B) Skull measurements, including width (A), length
(B), inner canthal distance (C), and nose widths (D), were taken of age- and gender-matched TLR4(lps−/−), DKO, and MPS VII male mice (n = 6). TLR4(lps−/−) mice
had skull measurements that were equivalent to normal. A signiﬁcant increase in skull length and reduction in width were observed in the DKO mice compared
with the MPS VII mice. *P < 0.001. (C) Micro-CT analysis was performed on femora from TLR4(lps−/−), DKO, and MPS VII male mice (n = 6). A representative image
is shown, revealing that the bones were signiﬁcantly longer in DKO vs. MPS VII mice. (D) Representative images of the growth pla es from TLR4(lps−/−), MPS
VII, and DKO mice. Note that the growth plates were thinner in DKO vs. MPS VII mice and that the columns were more organized. (Scale bar: 15 μm.) (E) Levels
of p-STAT1-Ser727 (90 kDa) and p-STAT3-Tyr705 (90 kDa) were analyzed by Western blotting in normal, MPS VII, TLR4(lps−/−), and DKO mice. β-Actin was used as
a loading control (46 kDa). MPS VII mice had elevated p-STAT1-Ser727 and reduced p-STAT3-Tyr705; these were corrected in the DKO mice. (F) TNF-α serum
levels were analyzed by ELISA in 5-month-old TLR4(lps−/−) (gray bar), MPS VII (white bar), and DKO (black bar) mice (n = 6). Signiﬁcantly elevated TNF-α levels
were evident in the MPS VII mice, which were normalized in the DKOmice. (G) ale 5-month-old TLR4(lps−/−) (gray bar), MPS VII (white bar), and DKO (black ar)
mice were placed on an accelerating rotarod to assess coordination and mobility (n = 6). The MPS VII mice could not complete the task and fell off between
54 (0.38 m) and 75 (0.70 m) sec after initiating the run. In contrast, the DKO mice completed the 120-sec (1.4 m) task, equivalent to the control TLR4(lps−/−) mice.
*P < 0.001.
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•  An=-­‐TLR4	   monoclonal	   an=bodies	   administra=on	   will	  
improve	  the	  vector	  tropism	  in	  bones	   	  joints.	  
•  β-­‐glucuronidase	  ac=v ty	   nd	  GAGs	  accumula=on	  in	  the	  
main	  =ssues	  will	  be	  restored.	  Also	  in	  chondrocytes	  and	  
osteoblasts	  that	  will	  mean	  longer	  and	  shapely	  bones.	  
•  MPS	   VII	   trea ed	   dogs	   will	   hav 	   longer	   survival	  
xpectancy	  t an	  untreated	  MPS	  VII	  dogs.	  
	  
	  
	  
	  
	  
HCl, and total calcium content wasmeasured using the o-cresolphthalein
complexone technique [27]. Sulfated GAG and calcium were normalized
to the sample dry weight. These analyses were undertaken for 3 6-
month-old RV-treatedMPSVII dogs, and compared to results for 4 normal
and 4 untreated MPS VII dogs analyzed previously [18].
2.5. Statistical analysis
Results are presented as mean±standard deviation. Values for
normal, untreated MPS VII, and RV-treated MPS VII dogs were
compared using ANOVA with Holm–Sidak post-hoc analysis (Sigma
Plot 12; Systat Software Inc, Chicago, IL, USA). Kaplan–Meier log-rank
survival analysis was also undertaken using this software.
3. Results
3.1. MPS VII dog survival with RV treatment
MPS VII dogs were injected IV at 2 to 3 days after birth with the RV
designated hAAT-cGUSB-WPRE. This was previously demonstrated to
result in transduction of liver cells, which could secrete M6P-modiﬁed
GUSB into serum, afterwhich the enzymewas taken up by cells in other
tissues in a fashion analogous to ERT [2 ]. Twenty dogs have been
treatedwith neonatal RV since the initiation of this gene therapy project
in 2000. M1287 is designated as the HGF/RV-treated MPS VII dog, who
was treated as detailed in themethods, andwas sacriﬁced at 11 years of
age for poor mobility.
The other 19 treated dogs did not receive any stimulus for
hepatocyte replication, and are designated RV-treated MPS VII dogs.
One RV-treated dog (M2159) had a marked fall in expression at
approximately 2 months after gene transfer that we hypothesize was
due to a cytotoxic T lymphocyte response to the normal canine GUSB
protein (similar to that seen in MPS I cats [28]), and was sacriﬁced at
4 months without any further clinical evaluation. Four dogs died
suddenly of an unclear etiology after gene transfer (two at 1 week,
and two at 3 months). For the other 14 RV-treated MPS VII dogs, 3 are
still alive at 2 to 3 year of age, and 7 were sacriﬁced at 6 months to
5 years after g ne transfer for the collection of tissues, but did not have
any serious clinical signs. Of the 4 other RV-treated dogs, two were
sacriﬁced at 6 or 10 years for po rmobility, onewas sacriﬁced at 8 years
for a benign hemangioma that turned out to express the RV (KPP and
MEH, unpublished data), and onewas sacriﬁced at 8 years for a forelimb
celluli is that did not heal with antibiotics. The Kaplan–Meier log-rank
survival curve of untreated and treated (both RV- and HGF/RV-treated)
MPS VII dogs is shown in Fig. 1A. The mean survival for the untreated
MPSVII dogswas 0.4 years, while themean survival for the treated dogs
was dramatically increased to 6.1 years (pb0.001). For normal
(GUSB+/− and GUSB+/+) dogs (not shown), approximately 10% died
in the ﬁrst month, but there w re f w spontaneous deaths thereafter.
Normal dogs were generally sacriﬁced while in good health.
3.2. Serum GUSB activity
Serum GUSB activity (Fig. 1B) is a simple measure of the level and
stability of expression, although achieving normal levels in blood does
not necessarily mean that enzyme can diffuse to all tissues. The average
serum GUSB activity for the entire RV-treated group was 884±
1093 U/ml (3.6-fold normal). The RV/HGF-treated MPS VII dog had
15,935 U/ml of GUSB activity in serum over his lifetime, which
was 65-fold normal, and more than 3-fold that for any other treated
animal.
3.3. Urinary G Gs
Urine GAGs are elevated in patients withMPS, and their reduction is
a commonly-used biomarker of improve ent with therapy. For
example, urine GAGs were reduced by 63% with ERT in patients with
MPS I [29] and by 49% with ERT in patients with MPS II [30], although
urine GAGs remained abov normal in m st patients in both f these
previous studies. In this study, untreated MPS VII dogs that were
6 months or older had urine GAG levels that were 119±23 μg of
GAG/mg of crea nine (N=20), whichwas 17-fold (pb0.001) the value
of 7.1±5.5 μg of GAG/mg of creatinine in normal dogs (N=55), as
shown in Fig. 1C. Treated MPS VII dogs (both HGF/RV- and RV-treated)
had 32±23 μg of GAG/mg of creatinine in urine at 6 months or older
(N=23, as the same dog was sometimes assayed more than once),
which represented a 74% reduction from the value in untreatedMPS VII
dogs (pb0.001 vs. MPS VII), but values remained 4-fold normal
(pb0.001 vs. normal).
3.4. adiographic analysis of RV-treated dogs at 3 o ths to 1 year of age
Radiographs were used to evaluate the time course of the
appearance of abnorm liti s in the lumbar spine. Representative
radiographs from 3 months to 1 year after birth for normal, untreated
MPS VII, and RV treatedMPS VII dogs are shown i Fig. 2. The end-plate
Fig. 1. Survival curves, serum GUSB activity, and urine GAGs. A. Survival of treated and untreated MPS VII dogs. MPS VII dogs were either untreated, or were injected with the RV
designated hAAT-cGUSB-WPRE at 2 to 3 days after birth. One dog (M1287 received HGF prior to injection of RV to attempt to induce hep tocyte repli ation and potentiate transduction,
while 19 dogs received RV without HGF. The survival of the indicated number of dogs using Kaplan–Meier log-rank survival analysis is shown. For the untreated MPS VII dogs, 34% died
spontaneously at a mean age of 1 month, 5% developed liver shunts with high blood ammonia and were euthanized at a mean age of 3 months, 43% were euthanized for other clinical
indications such as poormobility, sepsis, or pn umonia at amean age of 4 months, and 18%were sacriﬁced at am an age of 6 months for the collection of tissues andwere censored from
the survival curve. For the treatedMPS VII dogs, 4 dogs (20%) died spontaneously at a mean age of 2 months, 4 dogs (25%) were euthanized for musculoskeletal abnormalities at a mean
age of 8.6 years (including the HGF/RV-treated dog M1287 at 11 years), 1 dog (5%) was euthanized for a hemangioma at 8 years (dog M1328), 1 dog (5%) lost expression of GUSB at an
early age andwas killedwithout a clinical indication andwas censored, 7 dogs (35%)were killed for the collection of tissueswithout clinical signs andwere censored, and 3 dogs (15%) are
still alive andwere censored. B. SerumGUSB activity. SerumGUSB activity for the HGF/RV-treatedMPS VII dogM1287 and for the RV-treatedMPS VII dogs at the indicated ages is shown.
Normal dogs had 284±55 U/ml (SD) as indicated by the yellow shaded box, while untreated MPS VII dogs had b1 U/ml, as indicated by the low initial value. C. Urine GAG. Urine GAGs
were normalized to creatinine levels for the indicated number of animals from each group at 6 months or older. The values were compared with ANOVA with Holm–Sidak post-hoc
analysis, and all groups were statistically different from each other with a p valueb0.001.
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HCl, and total calcium content wasmeasured using the o-cresolpht alein
complexone technique [27]. Sulfated GAG and calcium were normalized
to the sample dry weight. These analyses were undertaken for 3 6-
month-old RV-treatedMPSVII dogs, and c mpared to results for 4 normal
and 4 untreated MPS VII dogs analyzed previously [18].
2.5. Statistical analysis
Results are presented as mean±standard deviation. Values for
normal, untreated MPS VII, and RV-treated MPS VII dogs were
compared using ANOVA with Holm–Sidak post-hoc analysis (Sigma
Plot 12; Systat Software Inc, Chicago, IL, USA). Kaplan–Meier log-rank
survival analysis was also undertaken using this software.
3. Results
3.1. MPS VII dog survival with RV treatment
MPS VII dogs were injected IV at 2 to 3 days after birth with the RV
designated hAAT-cGUSB-WPRE. This was previously demo strated to
result in transduction of liver c lls, which could secrete M6P- odiﬁed
GUSB into serum, afterwhich the enzymewas taken p by cells in other
tissues in a fashion analogous to ERT [21]. Twenty ogs have been
treatedwith neonatal RV since the initiation of this gene therapy project
i 2000. M1287 is designated as the HGF/RV-treated MPS VII og, who
was treated as detailed in themethods, andwas s criﬁced at 11 years of
age for poor mobility.
The other 19 treated dogs did not receive any stimulus for
hepatocyte replicati n, and are designated RV-treated MPS VII dogs.
One RV-treated dog (M2159) had a marked fall in expression at
approximately 2 months after gene transfer that we hypothesize was
due to a cytotoxic T lymphocyte response to the normal canine GUSB
protein (similar to that seen in MPS I cats [28]), and was sacriﬁced at
4 months without any further clinical evaluation. Four dogs died
suddenly of an unclear etiology after gene transfer (two at 1 week,
and two at 3 months). For the other 14 RV-treated MPS VII dogs, 3 are
still alive at 2 to 3 years of age, and 7 were sacriﬁced at 6 months to
5 years after gene transfer for the collection of tissues, but did not have
any serious clinical signs. Of the 4 other RV-treat d dogs, two were
sacriﬁced at 6 or 10 years for poormobili y, onewas sacriﬁced at 8 years
for a benign hemangioma that turned out to express the RV (KPP and
MEH, unpublished data), and onewas sacriﬁced at 8 y ars for a forelimb
cellulitis that did not heal with antibiotics. The Kaplan–Meier log-rank
survival curve of untrea ed and treated (both RV- and HGF/RV-t eated)
MPS VII d gs is sh wn in Fig. 1A. The mean survival for the untreated
MPSVII dogswas 0.4 years, while themean survival for the treated ogs
was dramatically increased to 6.1 years (pb0.001). For normal
(GUSB+/− and GUSB+/+) dogs (not shown), approximately 10% died
in the ﬁrst month, but th r were few spontaneous deaths thereafter.
Normal dogs were generally sacriﬁced while in good health.
3.2. Serum GUSB activity
Serum GUSB activity (Fig. 1B) is a simple m asure of the level and
stability of expression, although achieving normal levels in blood does
not necessarily mean that enzyme can diffuse to all tissues. The average
serum GUSB activity for the entire RV-treated group was 884±
1093 U/ml (3.6-fold normal). The RV/HGF-treated MPS VII dog had
15,935 U/ml of GUSB activity in serum over his lifetime, which
was 65-fold normal, and more than 3-fold that for any oth r treated
animal.
3.3. Urinary GAGs
Urine GAGs are elevated in patients withMPS, a d their reduction is
a commonly-used biomarker of improve ent with therapy. For
example, urine GAGs were reduced by 63% with ERT in patients with
MPS I [29] and by 49% with ERT in patients with MPS II [30], lthough
urine GAGs remained above normal in most patients in both of these
previous studies. In this study, untreated MPS VII dogs that were
6 months or older had urine GAG levels that were 119±23 μg of
GAG/mg of creatinine N=20), whichwas 17-fold (pb0.001) the value
of 7.1±5.5 μg of GAG/mg of creatinine i normal dogs (N=55), as
shown in Fig. 1C. Treated MPS VII dogs (both HGF/RV- and RV-treated)
had 32±23 μg of GAG/mg of creatinine in urine at 6 months or older
(N=23, as the same dog was sometimes assayed more than once),
which represented a 74% reduction from the value in untreatedMPS VII
dogs (pb0.001 vs. MPS VII), but values remained 4-fold normal
(pb0.001 vs. normal).
3.4. Radiographic analysis of RV-treated dogs at 3 months to 1 year of age
Radiographs were used to evaluate the time course of the
app arance of abno malities i t e lumbar spine. Repr sentative
radiographs from 3 months to 1 year after birth for nor al, untreated
MPS VII, and RV-treated PS VII dogs are shown in Fig. 2. The end-plate
Fig. 1. Survival curves, serum GUSB activity, and urine GAGs. A. Survival of treated and untreated MPS VII dogs. MPS VII dogs were either untreated, or were inject d with the RV
designated hAAT-cGUSB-WPRE at 2 to 3 days after birth. One dog (M1287) received HGF prior to injection of RV to attempt to induce hepatocyte replication and potentiate transduction,
while 19 dogs received RV without HGF. The survival of the indicated number of dogs using Kaplan–Meier log-rank survival analysis is shown. For the untreated MPS VII dogs, 34% died
spontaneously at a mean age of 1 month, 5% developed liver shunts with high blood ammonia and were uth nized at a mean age of 3 months, 43% were euthaniz d fo other clinical
indications such as poormobility, sepsis, or pneumonia at amean age of 4 months, and 18%were sacriﬁced at amean age of 6 months for the collection f tissues andwere censo ed from
the survival curve. For the treatedMPS VII dogs, 4 dogs (20%) died spontaneously at a mean age of 2 months, 4 dogs (25%) were euthanized for musculoskeletal ab ormalities t a mean
age of 8.6 years (including the HGF/RV-treated dog M1287 at 11 years), 1 dog (5%) was euthanized for a hemangioma at 8 years (dog M1328), 1 dog (5%) lost expressi n of GUSB at a
early age andwas killedwithout a clinical indication andwas censored, 7 dogs (35%)were killed for the collection of tissueswithout clinical signs andwere censored, and 3 dogs (15%) are
still alive andwere censored. B. SerumGUSB activity. SerumGUSB activity for the HGF/RV-treatedMPS VII dogM1287 and for the RV-treatedMPS VII dogs at the indicated ages is shown.
Normal dogs had 284±55 U/ml (SD) as indicated by the yellow shaded box, while untr ated MPS VII dogs had b1 U/ml, as indicated by the low initial value. C. Urine GAG. Urine GAGs
were normalized to creatinine levels for the indicated number of animals from each group at 6 months or older. Th values w re compared ith ANOVA with Holm–Sidak post-hoc
analysis, and ll groups were statistically differ nt from each oth r with a p valueb0.001.
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